Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Norma Henriquez

Psychiatry Naples, FL Medical Doctor

NPI 1053340976 CMS profile 274860

8795 Tamiami Trail, Suite 201, Room 2, Naples, FL 34113

Open in the dashboard

General payments

$4,062

103 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Norma Henriquez of Naples, FL is reported in the CMS Open Payments database as having received $4,062 across 103 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $291 15
2024 General $381 18
2023 General $1,940 28
2022 General $464 17
2021 General $521 14
2020 General $181 5
2019 General $284 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Norma Henriquez
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Norma Henriquez were reported at $291. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Norma Henriquez Psychiatry median Middle half National median
2019 $284 $184 $59–$605 $163
2020 $181 $119 $36–$372 $114
2021 $521 $143 $43–$576 $132
2022 $464 $153 $50–$590 $149
2023 $1,940 $170 $56–$651 $160
2024 $381 $179 $57–$673 $164
2025 $291 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neuronetics, Inc. $1,163 2 payments
  2. AbbVie, Inc. $1,032 36 payments
  3. ITI, Inc. $678 25 payments
  4. Otsuka America Pharmaceutical, Inc. $241 7 payments
  5. Allergan Inc. $236 2 payments
  6. Alkermes, Inc. $165 5 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $97 5 payments
  8. Axsome Therapeutics, Inc. $83 4 payments
  9. Almatica Pharma LLC $75 4 payments
  10. Janssen Pharmaceuticals, Inc $69 3 payments
  11. Other $224 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,275 100 payments
  2. Travel and Lodging $713 1 payment
  3. Education $74 2 payments
Products named General payments · program years 2019–2025
  1. Neurostar TMS Therapy System $1,163 2 payments
  2. VRAYLAR Neuroscience $959 32 payments
  3. CAPLYTA $661 24 payments
  4. VRAYLAR Neuroscience $309 6 payments
  5. ABILIFY MAINTENA $164 4 payments
  6. REXULTI $101 4 payments
  7. TRINTELLIX $97 5 payments
  8. VIVITROL $94 1 payment
  9. Auvelity $83 4 payments
  10. LOREEV XR $75 4 payments
  11. Other $826 41 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

2,753

Median for Psychiatry: 574

Drug cost

$95,329

Median for Psychiatry: $27,624

Branded share of claims

20.5%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 18 $25,814
Trintellix Vortioxetine Hydrobromide Brand 35 $17,854
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 73 $11,184
Zubsolv Buprenorphine Hcl/Naloxone Hcl Brand 15 $7,572
Quetiapine Fumarate Generic 257 $3,340
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 92 $3,166
Buprenorphine Hcl Generic 101 $2,418
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 88 $2,200
Mirtazapine Generic 136 $2,143
Oxcarbazepine Generic 82 $1,605

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$49,978

Medicare's payments for the services billed

Medicare patients

61

Average age 69

Services billed

630

40 women, 21 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 72%
High blood pressure 57%
Arthritis 57%
COPD 25%
Chronic kidney disease 20%
Ischemic heart disease 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $157
$157 18 —
COBENFY
  • E.R. Squibb & Sons, L.L.C. $53
$53 — —
Auvelity
  • Axsome Therapeutics, Inc. $46
$46 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $26
$26 — —
Zubsolv
  • Orexo US, Inc. $24
$24 15 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

103 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record